Sanofi India

'Sanofi India' - 33 News Result(s)

  • Sanofi, GlaxoSmithKline Get India's Approval For Late-Stage Vaccine Trial
    World News | Reuters | Thursday July 8, 2021
    Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.
    www.ndtv.com
  • Sanofi India Q3 Net Jumps 11% To Rs 81 Crore
    Business | Press Trust of India | Tuesday November 8, 2016
    The company had posted a net profit of Rs 72.5 crore in the same quarter last fiscal, Sanofi India said in a BSE filing.
    www.ndtv.com/business
  • Painkiller Combiflam Runs Into Trouble, Some Batches Withdrawn
    India News | Agencies | Thursday May 12, 2016
    The popular painkiller Combiflam is being withdrawn in batches in India after the country's drugs regulator found the lots were substandard, said the local unit of French drugmaker Sanofi.
    www.ndtv.com
  • Sanofi Recalls Some Batches Of Painkiller Combiflam In India
    Business | Thomson Reuters | Thursday May 12, 2016
    India's Central Drugs Standard Control Organisation (CDSCO) said in notices posted on its website in February and April that it had found some batches of Combiflam to be "not of standard quality" as they failed disintegration tests.
    www.ndtv.com/business
  • Sanofi India Posts 25% Rise In Q1 Net Profit
    Business | Press Trust of India | Friday April 29, 2016
    Pharmaceuticals firm Sanofi India on Friday reported 24.96 per cent increase in net profit at Rs 80.6 crore for the first quarter ended March 31.
    www.ndtv.com/business
  • Indebted Tycoon Vijay Mallya To Step Down As Sanofi India Chairman
    Business | Thomson Reuters | Wednesday March 23, 2016
    Indian business tycoon Vijay Mallya, under pressure from banks to repay more than dollar 1 billion owed by his collapsed airline, has decided to not seek re-election as chairman of French drugmaker Sanofi's India unit, the company said.
    www.ndtv.com/business
  • Sanofi India Q4 Net Profit Rises 30% to Rs 120 Crore
    Business | Press Trust of India | Thursday February 4, 2016
    In a separate filing, Sanofi India said its Board has recommended a final dividend of Rs 25 per equity share of Rs 10 for the year ended December 31, 2015. An interim dividend of Rs 18 per equity share of Rs 10 had been paid in August 2015.
    www.ndtv.com/business
  • Sanofi Gets Philippines Approval to Market Dengue Prevention Vaccine
    Business | Press Trust of India | Wednesday December 23, 2015
    Sanofi Pasteur, the vaccines division of Sanofi, on Wednesday said the Food and Drug Administration of Philippines has granted marketing approval to its Dengvaxia vaccine to be licensed for the prevention of dengue in Asia.
    www.ndtv.com/business
  • Sanofi India Surges as Arm Gets Approval for First Anti-Dengue Vaccine
    Business | NDTV | Friday December 11, 2015
    Sanofi India shares advanced nearly 5 per cent to hit intraday high of Rs 4,450 after the Mexican government approved the world's first anti-dengue vaccine developed by France-based Sanofi Pasteur which is an arm of the India-listed Sanofi India.
    www.ndtv.com/business
  • Hope For India As World's First Anti-Dengue Vaccine Approved
    Health | Indo-Asian News Service | Thursday December 10, 2015
    At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.
    www.ndtv.com
  • Sanofi India Sells Building in Mumbai
    Business | Press Trust of India | Friday November 20, 2015
    Drug firm Sanofi India has sold its commercial property, land and a building known as 'Aventis House' in Mumbai, for Rs 111 crore.
    www.ndtv.com/business
  • Glenmark, Sanofi End Pact for New Multiple Sclerosis Therapy
    Business | Press Trust of India | Thursday October 29, 2015
    Glenmark Pharmaceuticals' licensing deal with Sanofi for a new molecule - Vatelizumab - aimed at treating multiple sclerosis (MS) has ended with the French drug major deciding against pursuing it as the molecule did not meet the primary efficacy endpoint.
    www.ndtv.com/business
  • Sanofi India Q3 Net Profit Rises 17% to Rs 72.5 Crore
    Business | Press Trust of India | Tuesday October 20, 2015
    Drug firm Sanofi India on Tuesday reported 16.93 per cent rise in its standalone net profit to Rs 72.5 crore for the third quarter ended September 30, 2015.
    www.ndtv.com/business
  • Sanofi India Posts 12% Rise in Q2 Profit
    Business | Press Trust of India | Tuesday July 21, 2015
    Drug firm Sanofi India on Tuesday reported an 11.65 per cent rise in standalone net profit at Rs 64.2 crore for the fiscal second quarter that ended on June 30, 2015.
    www.ndtv.com/business
  • Considering All Options Against CCI Order: GlaxoSmithKline
    Business | Monday June 8, 2015
    Slapped with a penalty of nearly Rs 61 crore by the Competition Commission of India (CCI), GlaxoSmithKline Pharmaceuticals said on Monday that it would review the order and consider all options, including filing an appeal.
    www.ndtv.com/business

'Sanofi India' - 2 Video Result(s)

'Sanofi India' - 33 News Result(s)

  • Sanofi, GlaxoSmithKline Get India's Approval For Late-Stage Vaccine Trial
    World News | Reuters | Thursday July 8, 2021
    Sanofi SA and GlaxoSmithKline Plc have received an approval from Indian authorities for a late-stage clinical trial of their protein-based COVID-19 vaccine candidate, the drugmakers said on Thursday.
    www.ndtv.com
  • Sanofi India Q3 Net Jumps 11% To Rs 81 Crore
    Business | Press Trust of India | Tuesday November 8, 2016
    The company had posted a net profit of Rs 72.5 crore in the same quarter last fiscal, Sanofi India said in a BSE filing.
    www.ndtv.com/business
  • Painkiller Combiflam Runs Into Trouble, Some Batches Withdrawn
    India News | Agencies | Thursday May 12, 2016
    The popular painkiller Combiflam is being withdrawn in batches in India after the country's drugs regulator found the lots were substandard, said the local unit of French drugmaker Sanofi.
    www.ndtv.com
  • Sanofi Recalls Some Batches Of Painkiller Combiflam In India
    Business | Thomson Reuters | Thursday May 12, 2016
    India's Central Drugs Standard Control Organisation (CDSCO) said in notices posted on its website in February and April that it had found some batches of Combiflam to be "not of standard quality" as they failed disintegration tests.
    www.ndtv.com/business
  • Sanofi India Posts 25% Rise In Q1 Net Profit
    Business | Press Trust of India | Friday April 29, 2016
    Pharmaceuticals firm Sanofi India on Friday reported 24.96 per cent increase in net profit at Rs 80.6 crore for the first quarter ended March 31.
    www.ndtv.com/business
  • Indebted Tycoon Vijay Mallya To Step Down As Sanofi India Chairman
    Business | Thomson Reuters | Wednesday March 23, 2016
    Indian business tycoon Vijay Mallya, under pressure from banks to repay more than dollar 1 billion owed by his collapsed airline, has decided to not seek re-election as chairman of French drugmaker Sanofi's India unit, the company said.
    www.ndtv.com/business
  • Sanofi India Q4 Net Profit Rises 30% to Rs 120 Crore
    Business | Press Trust of India | Thursday February 4, 2016
    In a separate filing, Sanofi India said its Board has recommended a final dividend of Rs 25 per equity share of Rs 10 for the year ended December 31, 2015. An interim dividend of Rs 18 per equity share of Rs 10 had been paid in August 2015.
    www.ndtv.com/business
  • Sanofi Gets Philippines Approval to Market Dengue Prevention Vaccine
    Business | Press Trust of India | Wednesday December 23, 2015
    Sanofi Pasteur, the vaccines division of Sanofi, on Wednesday said the Food and Drug Administration of Philippines has granted marketing approval to its Dengvaxia vaccine to be licensed for the prevention of dengue in Asia.
    www.ndtv.com/business
  • Sanofi India Surges as Arm Gets Approval for First Anti-Dengue Vaccine
    Business | NDTV | Friday December 11, 2015
    Sanofi India shares advanced nearly 5 per cent to hit intraday high of Rs 4,450 after the Mexican government approved the world's first anti-dengue vaccine developed by France-based Sanofi Pasteur which is an arm of the India-listed Sanofi India.
    www.ndtv.com/business
  • Hope For India As World's First Anti-Dengue Vaccine Approved
    Health | Indo-Asian News Service | Thursday December 10, 2015
    At a time when India is struggling with rising number of dengue cases with each passing year, the Mexican government has approved the world's first anti-dengue vaccine which is designed to protect people in the 9-45 age group from nine to 45 years from all four subtypes of the virus.
    www.ndtv.com
  • Sanofi India Sells Building in Mumbai
    Business | Press Trust of India | Friday November 20, 2015
    Drug firm Sanofi India has sold its commercial property, land and a building known as 'Aventis House' in Mumbai, for Rs 111 crore.
    www.ndtv.com/business
  • Glenmark, Sanofi End Pact for New Multiple Sclerosis Therapy
    Business | Press Trust of India | Thursday October 29, 2015
    Glenmark Pharmaceuticals' licensing deal with Sanofi for a new molecule - Vatelizumab - aimed at treating multiple sclerosis (MS) has ended with the French drug major deciding against pursuing it as the molecule did not meet the primary efficacy endpoint.
    www.ndtv.com/business
  • Sanofi India Q3 Net Profit Rises 17% to Rs 72.5 Crore
    Business | Press Trust of India | Tuesday October 20, 2015
    Drug firm Sanofi India on Tuesday reported 16.93 per cent rise in its standalone net profit to Rs 72.5 crore for the third quarter ended September 30, 2015.
    www.ndtv.com/business
  • Sanofi India Posts 12% Rise in Q2 Profit
    Business | Press Trust of India | Tuesday July 21, 2015
    Drug firm Sanofi India on Tuesday reported an 11.65 per cent rise in standalone net profit at Rs 64.2 crore for the fiscal second quarter that ended on June 30, 2015.
    www.ndtv.com/business
  • Considering All Options Against CCI Order: GlaxoSmithKline
    Business | Monday June 8, 2015
    Slapped with a penalty of nearly Rs 61 crore by the Competition Commission of India (CCI), GlaxoSmithKline Pharmaceuticals said on Monday that it would review the order and consider all options, including filing an appeal.
    www.ndtv.com/business

'Sanofi India' - 2 Video Result(s)

Your search did not match any documents
A few suggestions
  • Make sure all words are spelled correctly
  • Try different keywords
  • Try more general keywords
Check the NDTV Archives:https://archives.ndtv.com